CytoDyn Inc. (CYDY) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US23283M1018
CytoDyn Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Operating income | 9.66 m USD | -38.58 m USD |
| EBIT | 3.18 m USD | -42.96 m USD |
| Net income | 3.75 m USD | -42.70 m USD |
| Diluted EPS – continuing operations | 0.00 USD | -0.03 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CytoDyn Inc.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
More stocks
- Shenke Slide Bearing Corp (002633.SZ)
- Tonnellerie Francois Freres SA (TFF.PA)
- Zhejiang Dayang Biotech Group Co (003017.SZ)
- Perfect Group Corp Ltd Class A (603059.SS)
- PERMA FIX ENVIRONMENTAL SERVICES INC (PESI)
- Cooper-Standard Holdings Inc. (CPS)
- ENANTA PHARMACEUTICALS INC (ENTA)
- Shenzhen Tongyi Industry Co Ltd (300538.SZ)
- OFFICE PROPERTIES INCOME TRUST (OPI)
- Yaxing Chem (600319.SS)
- Ernst Russ (ERAG.DE)
- Yummies Inc (YUMM)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.